Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials.

× No keyword cloud information.

22 in total

Review 1. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

Authors: A D Harris; T B Karchmer; Y Carmeli; M H Samore
Journal: Clin Infect Dis Date: 2001-03-21 Impact factor: 9.079

Review 2. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors:
Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875

3. Risks in new drug development: approval success rates for investigational drugs.

Authors: J A Dimasi
Journal: Clin Pharmacol Ther Date: 2001-05 Impact factor: 6.875

4. Scientific value and validity as ethical requirements for research: a proposed explication.

Authors: Benjamin Freedman
Journal: IRB Date: 1987 Nov-Dec

5. Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions.

Authors: John H Powers
Journal: Stat Med Date: 2008-02-10 Impact factor: 2.373

6. Excess deaths associated with tigecycline after approval based on noninferiority trials.

Authors: Paritosh Prasad; Junfeng Sun; Robert L Danner; Charles Natanson
Journal: Clin Infect Dis Date: 2012-03-30 Impact factor: 9.079

7. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.

Authors: Thomas R Fritsche; Patty A Strabala; Helio S Sader; Michael J Dowzicky; Ronald N Jones
Journal: Diagn Microbiol Infect Dis Date: 2005-07 Impact factor: 2.803

Review 8. Issues in noninferiority trials: the evidence in community-acquired pneumonia.

Authors: Thomas R Fleming; John H Powers
Journal: Clin Infect Dis Date: 2008-12-01 Impact factor: 9.079

9. Design, conduct, and analysis of clinical trials in disease due to methicillin-resistant Staphylococcus aureus.

Authors: J H Powers; T R Fleming
Journal: Clin Pharmacol Ther Date: 2009-09 Impact factor: 6.875

10. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.

Authors: Peter E Pertel; Patricia Bernardo; Charles Fogarty; Peter Matthews; Rebeca Northland; Mark Benvenuto; Grace M Thorne; Steven A Luperchio; Robert D Arbeit; Jeff Alder
Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079

3 in total

1. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.

Authors: Y-T Lee; S-M Tsao; P-R Hsueh
Journal: Eur J Clin Microbiol Infect Dis Date: 2013-04-05 Impact factor: 3.267

Review 2. The evolution of the regulatory framework for antibacterial agents.

Authors: John H Rex; Mark Goldberger; Barry I Eisenstein; Carrie Harney
Journal: Ann N Y Acad Sci Date: 2014-05-02 Impact factor: 5.691

Review 3. The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.

Authors: Aura Rusu; Emanuela Lorena Buta
Journal: Pharmaceutics Date: 2021-12-05 Impact factor: 6.321

3 in total